logo
Select company
Select metric
$ -256.75MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
3
Sector
6
Industry
7
History
14
$ 12.96Close
$ 2.29 - $ 18.94 52-Week Range
Ticker Information

Ticker

PHAT

Company Name

PHATHOM PHARMACEUTICALS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

PHATHOM PHARMACEUTICALS INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

PHAT - EBITDA Historical data
DateDepreciation, Amortization & AccretionEarning Before Interest & Taxes (EBIT)Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
6/30/2025$ 733K$ -257.49M$ -256.75M
3/31/2025$ 758K$ -272.88M$ -272.12M
12/31/2024$ 795K$ -262.32M$ -261.52M
9/30/2024$ 787K$ -273M$ -272.21M
6/30/2024$ 717K$ -239.04M$ -238.33M
3/31/2024$ 643K$ -196.71M$ -196.07M
12/31/2023$ 575K$ -159.62M$ -159.05M
9/30/2023$ 558K$ -138.53M$ -137.97M
6/30/2023$ 612K$ -147.21M$ -146.59M
3/31/2023$ 638K$ -161.11M$ -160.47M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • PHATHOM PHARMACEUTICALS INC's latest trailing twelve months (TTM) EBITDA stands at $ -168.81M.
  • Over the past 5 years, PHATHOM PHARMACEUTICALS INC's average EBITDA has been $ -179.88M.
  • The median EBITDA for PHATHOM PHARMACEUTICALS INC during this period was $ -158.24M
  • PHATHOM PHARMACEUTICALS INC reached its highest EBITDA over the past 5 years at $ -124.16M.
  • The lowest EBITDA recorded by PHATHOM PHARMACEUTICALS INC in the same timeframe $ -272.21M

PHATHOM PHARMACEUTICALS INC's EBITDA vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDA Benchmarks
CompanyEBITDA
GYRE : GYRE THERAPEUTICS INC $ 9.86MANAB : ANAPTYSBIO INC $ -130.11MNAGE : NIAGEN BIOSCIENCE INC $ 19.78MCRMD : CORMEDIX INC $ 52.25MTBPH : THERAVANCE BIOPHARMA INC $ 48.42MZYME : ZYMEWORKS INC $ -54.55MURGN : UROGEN PHARMA LTD $ -134.34MZVRA : ZEVRA THERAPEUTICS INC $ 36.45MXNCR : XENCOR INC $ -123.36MKURA : KURA ONCOLOGY INC $ -192.46M

Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
EBIT + DepAmor
(=) EBITDA
EBITDA for PHATHOM PHARMACEUTICALS INC is calculated as follows: EBIT [ $ -169.03M ] + DepAmor [ $ 223K ]
(=) EBITDA [ $ -168.81M ]

PHAT - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years

$ -272.21M

Minimum

Sep 30, 2024

$ -124.16M

Maximum

Dec 31, 2020

$ -179.88M

Average

$ -158.24M

Median

EBITDA Benchmark Analysis

The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.79M with a standard deviation of $ 166.94M.
The following table provides additional summary stats:
EBITDA in the Market:
filtered constituents3.25K
min$ -493.3M
max$ 590.6M
average$ 58.79M
median$ 8.83M
std$ 166.94M